The Effect of Oral Mucositis on Morbidity and Mortality in Bone Marrow Transplant

Seminars in Oncology

Volumn 30, Issue 6 SUPPL. 18, 2003, Pages 76-83

  Gabriel, Don A ^a   Shea, Thomas ^a   Olajida, Oludamilola ^a   Serody, Jonathan S ^a   Comeau, Terrance ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; BUSULFAN; CALCIUM PHOSPHATE; CARBOPLATIN; CARMUSTINE; CEFTAZIDIME; CLINDAMYCIN; COLLAGEN; CREATININE; CYCLOPHOSPHAMIDE; CYTOKINE; ETOPOSIDE; FLUORIDE; FLUOROURACIL; GLUTAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMMUNOGLOBULIN; INTERLEUKIN 11; KERATINOCYTE GROWTH FACTOR; MELPHALAN; MORPHINE; POLYPEPTIDE ANTIBIOTIC AGENT; RETINOIC ACID; SUCRALFATE; THIOTEPA;

BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DRUG EFFICACY; HEAD AND NECK CANCER; HEALTH CARE COST; HEMATOLOGIC MALIGNANCY; HUMAN; INFRARED RADIATION; LASER; MORBIDITY; MORTALITY; MOUTH HYGIENE; MOUTH MUCOSA; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; SOLID TUMOR; WHOLE BODY RADIATION;

EID: 1642517256     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.11.040     Document Type: Conference Paper

References (64)

1. Filicko J, Lazarus HM, Flomenberg N: Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: New approaches to prophylaxis and treatment. Bone Marrow Transplant 31:1-10, 2003
2. Godder KT, Henslee-Downey PJ: Colony-stimulating factors in stem cell transplantation: Effect on quality of life. J Hematother Stem Cell Res 10:215-228, 2001
3. Epstein JB, Schubert MM: Oral mucositis in myelosuppressive cancer therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88:272-276, 1999
4. Carl W: Oral complications of local and systemic cancer treatment. Curr Opin Oncol 7:320-324, 1995
5. Phillips GL III: The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Semin Oncol 29:53-56, 2002 (suppl 19)
6. Sonis ST, Oster G, Fuchs H, et al: Oral mucositis and the clinical and economic outcomes of hematopoietic stem cell transplantation. J Clin Oncol 19:2201-2205, 2001
7. Bennett CL, Lane D, Stinson T, et al: Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: Preliminary results from a randomized phase II clinical trial from Germany. Cancer Invest 19:107-113, 2001
8. Labarca JA, Leber AL, Kern VL, et al: Outbreak of stenotrophomonas maltophilia bacteremia in allogeneic bone marrow transplant patients: Role of severe neutropenia and mucositis. Clin Infect Dis 30:195-197, 2000
9. Eisen D, Essell J, Broun ER: Oral cavity complications of bone marrow transplantation. Semin Cutan Med Surg 16:265-272, 1997
10. Shea TC, Brunner R, Wiley JM, et al: Biol Blood Marrow Transplant 9:443-452, 2003
11. McGuire DB, Altomonte V, Peterson DE, et al: Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum 20:1493-1502, 2003
12. Woo SB, Sonis ST, Monopole MM, et al: A longitudinal study of oral uncreative mucositis in bone marrow transplant recipients. Cancer 72:1612-1617, 1993
13. Wardley AM, Jayson GC, Swindell R, et al: Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol 110:292-299, 2000
14. McGuire DB, Yeager KA, Dudley WN, et al: Acute oral pain and mucositis in bone marrow transplant and leukemia patients: Data from a pilot study. Cancer Nurs 21:385-393, 1998
15. McGuire DB, Peterson DE, Muller S, et al: The 20 item oral mucositis index: Reliability and validity in bone marrow and stem cell transplant patients. Cancer Invest 20:893-903, 2002
16. Bellm LA, Cunningham G, Durnell L, et al: Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: Oral mucositis patient provider advisory board. Cancer Invest 20:793-800, 2002
17. Walsh LJ, Hill G, Seymour G, et al: A scoring system for the quantitative evaluation of oral mucositis during bone marrow transplantation. Spec Care Dentist 10:190-195, 1990
18. Tardieu C, Cowen D, Thirion X, et al: Quantitative scale of oral mucositis associated with autologous bone marrow transplantation. Eur J Cancer B Oral Oncol 32B:331-337, 1996
19. Donaldson GW: The factorial structure and stability of the McGill Pain Questionnaire in patients experiencing oral mucositis following bone marrow transplant. Pain 62:101-109, 1995
20. Schubert MM, Williams BE, Lloid ME, et al: Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer 69:2469-2477, 1992
21. Blijlevens NM, Donnelly JP, DePauw BE: Mucosal barrier injury: Pathology, clinical counterparts and consequences of intensive treatment for haematological malignancies: An overview. Bone Marrow Transplant 25:1269-1278, 2000
22. Alvarado Y, Bellm LA, Giles FJ: Oral Mucositis: Time for more studies. Hematology 7:281-289, 2002
23. Verdi CJ: Cancer therapy and oral mucositis. An appraisal of drug prophylaxis. Drug Saf 9:185-95, 1993
24. Epstein JB, Tsang AH, Warkentin D, et al: The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis: A review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 94:39-44, 2002
25. Stiff P: Mucositis associated with stem cell transplantation: Current status and innovative approaches to management. Bone Marrow Transplant 27:S3-S11, 2001 (suppl 2)
26. Sonis ST, Peterson RL, Edwards LJ, et al: Defining mechanisms of action of interleukin 11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 36: 373-381, 2001
27. Kostler WJ, Hejna M, Wenzel C, et al: Oral mucositis complicating chemotherapy and/or radiotherapy: Options for prevention and treatment. CA Cancer J Clin 51:290-315, 2001
28. Garfunkel AA, Tager N, Chausu S, et al: Oral complications in bone marrow transplantation patients: Recent advances. Isr J Med Sci 30:120-124, 1994
29. Lark RL, McNeil SA, VanderHyde K, et al: Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin Infect Dis 33:338-343, 2001
30. Ruescher TJ, Sodeifi A, Scrivani SJ, et al: The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 82:2275-2281, 1998
31. Donnelly JP, Muus P, Horrevorts AM, et al: Failure of clindamycin to influence the course of severe oromucositis associated with streptococcal bacteremia in allogeneic bone marrow transplant recipients. Scand J Infect Dis 25:43-50, 1993
32. Lucas VS, Beighton D, Roberts GJ, et al: Changes in the oral streptococcal flora of children undergoing allogeneic bone marrow transplantation. J Infect 35:135-141, 1997
33. Classen DC, Burke JP, Ford CD, et al: Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. Am J Med 89:441-446, 1990
34. Rapport AP, Miller Watelet LF, Linder T, et al: Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol 17: 2446-2453, 1999
35. Murray JC, Chiu JK, Dorfman SR, et al: Epiglottitis following preparation for allogeneic bone marrow transplantation. Bone Marrow Transplant 15:997-998, 1995
36. Lee L, Miller PA, Maxymiw WG, et al: Intraoral pyogenic granuloma after allogeneic bone marrow transplant. Report of three cases. Oral Surg Oral Med Oral Pathol 73:607-610, 1994
37. Borowski B, Benhamou E, Pico JL, et al: Prevention of oral mucositis in patients treated with high-dose chemotherapy and bone marrow transplantation: A randomized controlled trail comparing two protocols of dental care. Eur J Cancer B Oral Oncol 30B:93-97, 1994
38. Papas AS, Clark RE, Martuscelli G, et al: A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 31:705-712, 2003
39. Whelan HT, Connelly JF, Hodgson BD, et al: NASA light-emitting diodes for the prevention of oral mucositis in pediatric bone marrow transplant patients. J Clin Laser Med Surg 20:319-324, 2002
40. Cowen D, Tardieu C, Schubert M, et al: Low energy helium-neon laser in the prevention of oral mucositis in patients undergoing bone marrow transplant: Results of a double blind randomized trial. Int J Radiat Oncol Biol Phys 38:697-703, 1997
41. Pourreau-Schneider N, Ahmed A, Soudry M, et al: Helium-Neon laser treatment transforms fibroblast into myosbroblast. Am J Pathol 137:171-178, 1990
42. Antin JH, Lee SJ, Neuberg D, et al: A phase I/II double-blind, placebo-controlled study of recombinant human interleukin 11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant 29:373-377, 2002
43. Castanga L, Benhamou E, Pedraza E, et al: Prevention of mucositis in bone marrow transplantation: A double blind randomized controlled trial of sucralfate. Ann Oncol 12:953-955, 2001
44. Coghlin-Dickson TM, Wong RM, Offrin RS, et al: Effect of oral glutamine supplementation during bone marrow transplantation. JPEN J Parenter Enteral Nutr 24:61-66, 2000
45. Bez C, Demarosi F, Sardella A, et al: GM-CSF mouth-rinses in the treatment of severe oral mucositis: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 88:311-315, 1999
46. Cohen G, Elad S, Or R, et al: The use of tretinoin as oral mucositis prophylaxis in bone marrow transplantation patients: A preliminary study. Oral Dis 3:243-246, 1997
47. Gardina DJ, Murley JS, Kataoka Y: Radioprotectants: Current status and new directions. Oncology 63:2-10, 2002 (suppl 2)
48. Bizel DW, Wasserman TH, Henke M, et al: Phase III randomized trial of amifostine as a radioprotector of the head and neck. J Clin Oncol 18:3339-3345, 2000
49. Rudat V, Meyer J, Momm F, et al: Protective effect of amifostine on dental health after radiotherapy of the head and neck. Int J Radiat Oncol Biol Phys 48:1339-1343, 2000
50. Antonadou D, Pepelassi M, Synodinou M, et al: Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 52:739-747, 2002
51. Wasserman T, Mackowiak JL, Brizel DM, et al: Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. Int J Radiat Oncol Biol Phys 48:1035-1039, 2000
52. Capizzi RL: The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol 26:3-21, 1999
53. Shea T, Brunner R, Wiley JM, et al: An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for patients with hematologic malignancies. Biol Blood Marrow Transplant 9:443-452, 2003
54. Capelli D, Santini G, DeSouza C, et al: Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: A retrospective study. Br J Haematol 110:300-3007, 2000
55. Phillips GL II: The potential of amifostine in high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Semin Oncol 29:53-56, 2002 (suppl 19)
56. Thieblemont C, Dumonet C, Saad H, et al: Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 30:769-775, 2002
57. Hatrmann JT, von Vangerow A, Fels LM, et al: A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation. Br J Cancer 84:313-320, 2001
58. Chauncey TR, Gooley TA, Lloid ME, et al: Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Am J Clin Oncol 23:406-411, 2000
59. Bocca R: Improved tolerability of amifostine with rapid infusion and optimal patient preparation. Semin Oncol 29:9-13, 2002 (suppl 19)
60. Giles FJ, Redman R, Yazji S, et al: Iseganan HCl: A novel antimicrobial agent. Expert Opin Invest Drugs 11:1161-1170, 2002
61. Danilenko DM: Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor. Toxicol Pathol 27:64-71, 1999
62. Anderson R, Gohari-Fritsch S, Olsen H, et al: In vitro and in vivo effects of repifermin (keratinocyte growth factor-2, KGF-2) on human carcinoma cells. Cancer Chemother Pharmacol 50:202-212, 2002
63. Meropol NJ, Somer RA, Gutheil J, et al: Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: Potential role as mucosal protectant. J Clin Oncol 21:1452-1458, 2003
64. Spielberger R, Emmanouilides C, Stiff P, et al: Use of recombinant keratinocyte growth factor (rHuKGF) can reduce severe oral mucositis in patients with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning: Results of a phase 3 trial. Proc Am Soc Clin Oncol 22;2003 (abstr 3642)